GeneDx Holdings Corp. (WGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) has a cash flow conversion efficiency ratio of -0.128x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.41 Million) by net assets ($254.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See WGS days of operational coverage to measure how many days the company can operate on defensive assets alone.
GeneDx Holdings Corp. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how GeneDx Holdings Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
GeneDx Holdings Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneDx Holdings Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sixt SE
XETRA:SIX3
|
0.081x |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
N/A |
|
United States Steel Corp
BA:X
|
-0.033x |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd A
SHG:600639
|
0.007x |
|
Beijing Sanju Environmental
SHE:300072
|
0.033x |
|
Ramsay Generale De Sante
PA:GDS
|
0.060x |
|
Ami Organics Limited
NSE:AMIORG
|
0.006x |
|
Instalco Intressenter AB
ST:INSTAL
|
0.133x |
Annual Cash Flow Conversion Efficiency for GeneDx Holdings Corp. (2020–2025)
The table below shows the annual cash flow conversion efficiency of GeneDx Holdings Corp. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see GeneDx Holdings Corp. (WGS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $308.18 Million | $33.28 Million | 0.108x | +192.94% |
| 2024-12-31 | $245.25 Million | $-28.50 Million | -0.116x | +85.29% |
| 2023-12-31 | $228.02 Million | $-180.15 Million | -0.790x | +37.20% |
| 2022-12-31 | $253.71 Million | $-319.15 Million | -1.258x | -156.37% |
| 2021-12-31 | $388.10 Million | $-190.43 Million | -0.491x | +97.69% |
| 2020-12-31 | $4.39 Million | $-93.13 Million | -21.223x | -- |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and can… Read more